IN THE CLAIMS

Please amend claims 17, 26, and 31 as indicated in the complete listing of all claims in the application set forth below.

Claim 15. (Previously Added) A composition comprising an antisense deoxyoligonucleotide having a sequence according to SEQ ID No. 1 or SEQ ID No. 2. and a pharmaceutically acceptable carrier or diluent.

Claim 16. (Previously Added) The composition according to claim 15 for use in combination with a thymidylate synthase inhibitor.

Claim 17. (Currently Amended) The composition according to claim 16, wherein the thymidylate synthase inhibitor is ~~Tomudex~~ N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid.

Claim 18. (Previously Added) The composition according to claim 15 for use in combination with an antiproliferative drug.

Claim 19. (Previously Added) The composition according to claim 18, wherein the anti-proliferative drug is selected from the group consisting of: methotrexate, 5-fluorouracil, FUdR, ftorafur, and FdUR.

Claim 20. (Previously Added) The composition according to claim 15, wherein the composition is in a conventional dosage form selected from the group consisting of: oral, topical, nasal, vaginal, rectal, inhalation, sub-lingual, buccal, and parenteral dosage forms.

Claim 21. (Previously Added) A method for inhibiting thymidylate synthase expression in mammalian tumor cells, comprising: administering to the mammalian tumor cells an antisense deoxyoligonucleotide having a sequence according to SEQ ID No: 1 or SEQ ID NO: 2, wherein the antisense deoxyoligonucleotide hybridizes to a target 3′ untranslated region of a mammalian thymidylate synthase nucleic acid and inhibits thymidylate synthase expression in said mammalian tumor cells.

Claim 22. (Previously Added) The method according to claim 21, wherein said antisense deoxyoligonucleotide is administered in an amount sufficient to inhibit tumor cell growth.

Claim 23. (Previously Added) The method according to claim 21, wherein said antisense deoxyoligonucleotide is administered in an amount sufficient to inhibit tumor cell proliferation.

Claim 24. (Previously Added) The method according to claim 21, wherein said antisense deoxyoligonucleotide is administered in an amount sufficient to sensitize mammalian tumor cells to an anticancer agent.

Claim 25. (Previously Added) The method according to claim 24, wherein the anticancer agent is selected from the group consisting of: a thymidylate synthase inhibitor, a cytostatic agent and an antiproliferative drug.

Claim 26. (Currently Amended) The method ~~of~~ according to claim 24, wherein the anticancer agent is selected from the group consisting of ~~Tomudex~~ N-(5-[N-(3,4-dihydro-2-methyl-4-

oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid, methotrexate, 5-fluorouracil, FUdR, ftorafur, and FdUR.

Claim 27. (Previously Added) The method according to claim 21, wherein the mammalian tumor cells are human tumor cells.

Claim 28. (Previously Added) The method according to claim 27, wherein the human tumor cells are selected from the group consisting of human breast cancer cells and human cervical cancer cells.

Claim 29. (Previously Added) A combination product comprising an antisense deoxyoligonucleotide having a sequence according to SEQ ID No: 1 or SEQ ID NO: 2 in combination with an anticancer agent, wherein the antisense deoxyoligonucleotide hybridizes to a 3′ untranslated region of a mammalian thymidylate synthase nucleic acid and inhibits thymidylate synthase expression in mammalian cells.

Claim 30. (Previously Added) The combination product according to claim 29, wherein the anticancer agent is selected

from the group consisting of: a thymidylate synthase inhibitor, a cytostatic agent, and an antiproliferative drug.

Claim 31. (Currently Amended) The combination product according to claim 29, wherein the anticancer agent is selected from the group consisting of ~~Tomudex~~ N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid, methotrexate, 5-fluorouracil, FUdR, ftorafur, and FdUR.

Claim 32. (Previously Added) The composition according to claim 15, wherein the deoxyoligonucleotide is phosphorothioated, methoxy-ethoxy winged or contains a peptide nucleic acid backbone.

Claim 33. (Previously Added) The combination product according to claim 29, wherein the deoxyoligonucleotide is phosphorothioated, methoxy-ethoxy winged or contains a peptide nucleic acid backbone.

Claim 34. (Previously Added) A method for the treatment of cancer or for providing an anti-proliferative effect comprising

administering to a human an effective amount of the composition of claim 15.

Claim 35. (Previously Added) A method for the treatment of cancer or for providing an anti-proliferative effect comprising administering to a human an effective amount of the combination product of claim 29.